-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex Collaborators To Present Preclinical Data And Research From Studies Of GPX-002, Diabetes Gene Therapy, At ASGCT 28Th Annual Meeting

Benzinga·04/29/2025 11:40:13
Listen to the news

Novel Gene Therapy Program Offers a Promising Opportunity for Curative Therapy in Diabetes

AUSTIN, Texas, April 29, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have been selected to present at the upcoming American Society of Gene and Cell Therapy's (ASGCT) 28th Annual Meeting being held May 13-17, 2025 in New Orleans, Louisiana. The collaborators will present positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate.